Yongzhi Lu

FXR-mediated recruitment of PPP1CB suppresses SMAD2/3 phosphorylation to mitigate pulmonary fibrosis

This study identifies FXR as a suppressor of pulmonary fibrosis by interacting with PPP1CB to reduce SMAD2/3 phosphorylation, showing therapeutic potential with TERN101.

A novel AR molecular glue degrader via bivalent engagement of the N-terminal domain and RNF213-UBE2J2 complex

This paper introduces GZL626, a novel AR degrader that targets the N-terminal domain and RNF213-UBE2J2 complex, effectively degrading AR and AR-V7 and showing antitumor and antiviral activity.

Targeting the host factor HGS-viral membrane protein interaction in coronavirus infection

This study identifies HGS as a host factor critical for coronavirus infection and discovers RTB as a broad-spectrum antiviral by disrupting HGS-M protein interaction.

Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19

The paper identifies a potent orally bioavailable SARS-CoV-2 PLpro inhibitor with in vitro and in vivo antiviral activity against SARS-CoV-2 and related coronaviruses.

Discovery of resistance-resilient quinoline papain-like protease inhibitors through topology-constrained molecular generative design

This paper discovers a novel quinoline-based PLpro inhibitor, GZNL-2016, that remains effective against drug-resistant SARS-CoV-2 variants like Omicron BA.5 and XBB.1.